Prevention of atrial fibrillation in hypertension

Current Hypertension Reports

Volumn 10, Issue 3, 2008, Pages 175-181

  Aksnes, Tonje Amb ^a   Flaa, Arnljot ^b   Strand, Arne ^b   Kjeldsen, Sverre E ^b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; METOPROLOL; NITRATE; OLMESARTAN; PERINDOPRIL; PLACEBO; PROPAFENONE; RAMIPRIL; SOTALOL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MONOTHERAPY; MORTALITY; PRIMARY PREVENTION; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 56349168625     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-008-0034-x     Document Type: Review

References (50)

1. Go AS, Hylek EM, Phillips KA, et al.: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001, 285:2370-2375.
2. Wolf PA, D'Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22:312-318.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al.: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998, 98:946-952.
4. Wyse DG, Waldo AL, DiMarco JP, et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002, 347:1825-1833.
5. Kannel WB, Wolf PA, Benjamin EJ, Levy D: Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998, 82:2N-9N.
6. Healey JS, Baranchuk A, Crystal E, et al.: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005, 45:1832-1839.
7. Schmieder RE, Kjeldsen SE, Julius S, et al.: Reduced incidence of new onset atrial fibrillation with angiotensin II receptor blockade: the VALUE-trial. J Hypertens 2008, 26:403-411.
8. Mancia G, De BG, Dominiczak A, et al.: 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
9. Healey JS, Connolly SJ: Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003, 91:9G-14G.
10. Wachtell K, Lehto M, Gerdts E, et al.: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005, 45:712-719.
11. Gottdiener JS, Reda DJ, Williams DW, et al.: Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents. Circulation 1998, 98:140-148.
12. Klingbeil AU, Schneider M, Martus P, et al.: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115:41-46.
13. Fogari R, Mugellini A, Destro M, et al.: Losartan and prevention of atrial fibrillation recurrence in hypertensive patients. J Cardiovasc Pharmacol 2006, 47:46-50.
14. Connolly S, Yusuf S, Budaj A, et al.: Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events. Am Heart J 2006, 151:1187-1193.
15. Teo K, Yusuf S, Sleight P, et al.: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004, 148:52-61.
16. Yamashita T, Ogawa S, Aizawa Y, et al.: Randomized study of angiotensin II type 1 receptor blocker vs dihydropyridine calcium antagonist for the treatment of paroxysmal atrial fibrillation in patients with hypertension. Circ J 2006, 70:1318-1321.
17. Goette A, Breithardt G, Fetsch T, et al.: Angiotensin II antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial: rationale and study design. Clin Drug Investig 2007, 27:697-705.
18. Tardif JC, Talajic M: Perindopril and prevention of atrial fibrillation. Eur Heart J Suppl 2007, 9:E25-E29.
19. Van den Berg MP, Crijns HJ, Van Veldhuisen DJ, et al.: Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995, 1:355-363.
20. Madrid AH, Bueno MG, Rebollo JM, et al.: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002, 106:331-336.
21. Madrid AH, Marin IM, Cervantes CE, et al.: Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004, 5:114-120.
22. Ueng KC, Tsai TP, Yu WC, et al.: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003, 24:2090-2098.
23. Tveit A, Grundvold I, Olufsen M, et al.: Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol 2007, 120:85-91.
24. Aksnes TA, Flaa A, Strand A, Kjeldsen SE: Prevention of new-onset atrial fibrillation and its predictors with angiotensin II-receptor blockers in the treatment of hypertension and heart failure. J Hypertens 2007, 25:15-23.
25. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
26. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999, 354:1751-1756.
27. Pedersen OD, Bagger H, Køber L, Torp-Pedersen C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999, 100:376-380.
28. Vermes E, Tardif JC, Bourassa MG, et al.: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003, 107:2926-2931.
29. Alsheikh-Ali AA, Wang PJ, Rand W, et al.: Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J 2004, 147:1061-1065.
30. Pizzetti F, Turazza FM, Franzosi MG, et al.: Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001, 86:527-532.
31. Maggioni AP, Latini R, Carson PE, et al.: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005, 149:548-557.
32. Ducharme A, Swedberg K, Pfeffer MA, et al.: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006, 152:86-92.
33. Murray KT, Rottman JN, Arbogast PG, et al.: Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm 2004, 1:669-675.
34. Salehian O, Healey J, Stambler B, et al.: Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. Am Heart J 2007, 154:448-453.
35. Okin PM, Wachtell K, Devereux RB, et al.: Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006, 296:1242-1248.
36. Gerdts E, Wachtell K, Omvik P, et al.: Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial. Hypertension 2007, 49:311-316.
37. Nakashima H, Kumagai K, Urata H, et al.: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000, 101:2612-2617.
38. Allessie MA: Atrial electrophysiologic remodeling: another vicious circle? J Cardiovasc Electrophysiol 1998, 9:1378-1393.
39. Tsai CT, Lai LP, Lin JL, et al.: Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 2004, 109:1640-1646.
40. Chen YJ, Chen YC, Tai CT, et al.: Angiotensin II and angiotensin II receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 2006, 147:12-22.
41. National Institute for Health and Clinical Excellence (NICE): NICE/ British Hypertension Society hypertension guidelines. Available at http://www.nice.org.uk/nicemedia/pdf/CG034NICEguideline.doc. Accessed March 20, 2008.
42. Kühlkamp V, Schirdewan A, Stangl K, et al.: Use of metoprolol CR/ XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000, 36:139-146.
43. Bradley D, Creswell LL, Hogue CW Jr, et al.: Pharmacologic prophylaxis: American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. Chest 2005, 128:39S-47S.
44. Fuster V, Ryden LE, Cannom DS, et al.: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation - executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 2006, 48:854-906.
45. Nasr IA, Bouzamondo A, Hulot JS, et al.: Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007, 28:457-462.
46. Van Noord T, Van Gelder I, Tieleman RG, et al.: VERDICT: the Verapamil versus Digoxin Cardioversion Trial: a randomized study on the role of calcium lowering for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation. J Cardiovasc Electrophysiol 2001, 12:766-769.
47. De Simone A, Stabile G, Vitale DF, et al.: Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999, 34:810-814.
48. Lee SH, Yu WC, Cheng JJ, et al.: Effect of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000, 101:200-206.
49. L'Allier PL, Ducharme A, Keller PF, et al.: Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004, 44:159-164.
50. Gottdiener JS, Reda DJ, Massie BM, et al.: Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation 1997, 95:2007-2014.